𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Early tumor and leukemia response to alkyl-lysophospholipids in a phase I study

✍ Scribed by Dr Wolfgang E. Berdel; Hermann Schlehe; Ulrich Fink; Berthold Emmerich; Peter A. Maubach; Hans P. Emslander; Severin Daum; Johann Rastetter

Publisher
John Wiley and Sons
Year
1982
Tongue
English
Weight
727 KB
Volume
50
Category
Article
ISSN
0008-543X

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Cytotoxic activity in the serum of a pat
Cytotoxic activity in the serum of a patient with metastasizing nephroblastoma given intravenous infusions of alkyl-lysophospholipids in a phase I study
✍ Andreesen, Reinhard ;Arnold, Heidwolf ;LοΏ½hr, Georg W. πŸ“‚ Article πŸ“… 1982 πŸ› Springer-Verlag βš– 223 KB

In a phase I study a cytotoxic activity in the serum of a tumor patient given infusions of synthetic alkyl-lysophospholipid has been demonstrated. Serum samples collected after ALP infusions inhibited 3H-thymidine incorporation by human leukemic cells to an extent that correlated to the dose of ALP

Early response to therapy and outcome in
Early response to therapy and outcome in childhood acute lymphoblastic leukemia : A review
✍ Paul S. Gaynon; Anish A. Desai; Bruce C. Bostrom; Raymond J. Hutchinson; Beverly πŸ“‚ Article πŸ“… 1997 πŸ› John Wiley and Sons 🌐 English βš– 159 KB πŸ‘ 2 views

## Background: Early response to therapy is defined as the initial response prior to day 28 of treatment, the conventional time of marrow evaluation. the number of reports linking early response to therapy with the ultimate outcome of childhood acute lymphoblastic leukemia is substantial and growin

Immune responses to AAV in a phase I stu
Immune responses to AAV in a phase I study for Canavan disease
✍ S. W. J. McPhee; C. G. Janson; C. Li; R. J. Samulski; A. S. Camp; J. Francis; D. πŸ“‚ Article πŸ“… 2006 πŸ› John Wiley and Sons 🌐 English βš– 317 KB

## Abstract ## Background Canavan disease is a rare leukodystrophy with no current treatment. rAAV‐ASPA has been developed for gene delivery to the central nervous system (CNS) for Canavan disease. This study represents the first use of a viral vector in an attempt to ameliorate a neurodegenerativ

Cognitive testing in early phase clinica
Cognitive testing in early phase clinical trials: outcome according to adverse event profile in a Phase I study
✍ Alex Collie; Paul Maruff; Peter J. Snyder; Miss Amanda Darekar; John P. Huggins πŸ“‚ Article πŸ“… 2006 πŸ› John Wiley and Sons 🌐 English βš– 112 KB

## Abstract ## Background It has been proposed that objective cognitive testing provides additional information to that collected via adverse event (AE) recordings. However, in clinical trials of compounds with potentially negative effects on cognition, the results of cognitive testing may overlap